Bioline Rx (BLRX) Stock Statistics & Valuation Metrics

Bioline Rx has a market cap or net worth of ₪39.31M. The enterprise value is 21.57.

Bioline Rx has 2,620,977,300 shares outstanding. The number of shares has decreased by -2.65% in one year.

Bioline Rx’s return on equity (ROE) is -0.07 and return on invested capital (ROIC) is -33.24%.

The current PE Ratio of Bioline Rx is ―. Bioline Rx’s PEG ratio is 0.11.

In the last 12 months, Bioline Rx had revenue of 1.28M and earned -1.27M in profits. Earnings per share was >-0.01.

In the last 12 months, operating cash flow was -7.93M and capital expenditures 7.74M, giving a free cash flow of -7.96M billion.

Bioline Rx pays an annual dividend of ―, resulting in a dividend yield of ―

Bioline Rx upcoming earnings date is Aug 13, 2026, Before Open (Confirmed).

Bioline Rx as a current ratio of 1.95, with Debt / Equity ratio of 54.40%

In the past 12 months, Bioline Rx has paid 0.00 in taxes.

Bioline Rx EV to EBITDA ratio is -1.82, with an EV/FCF ratio of -2.20.

Bioline Rx has ₪17.35M in cash and marketable securities with ₪9.07M in debt, giving a net cash position of ₪8.28M billion.

Gross margin is 74.67%, with operating margin of -871.78%, and net profit margin of -99.58%.

The average price target for Bioline Rx is ―, which is 11.43% higher than the current price. The consensus rating is ―